Targeted and Untargeted Proteomics Approaches in Biomarker Development
暂无分享,去创建一个
Christoph H Borchers | Constance A. Sobsey | Constance A Sobsey | Sahar Ibrahim | Vincent R Richard | Vanessa Gaspar | Georgia Mitsa | Vincent Lacasse | René P Zahedi | Gerald Batist | C. Borchers | G. Batist | R. Zahedi | Georgia Mitsa | Vincent Lacasse | Vincent R. Richard | S. Ibrahim | Vanessa Gaspar | Vanessa P. Gaspar
[1] S. Carr,et al. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry , 2013, Nature Methods.
[2] James D Brooks,et al. Translational genomics: the challenge of developing cancer biomarkers. , 2012, Genome research.
[3] Christoph H Borchers,et al. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum , 2014, Expert review of proteomics.
[4] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[5] W. Catalona,et al. The Prostate Health Index: a new test for the detection of prostate cancer , 2014, Therapeutic advances in urology.
[6] E. Fung,et al. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. , 2010, Clinical chemistry.
[7] Darryl B. Hardie,et al. Molecular phenotyping of laboratory mouse strains using 500 multiple reaction monitoring mass spectrometry plasma assays , 2018, Communications Biology.
[8] E. Diamandis,et al. Cancer biomarkers: can we turn recent failures into success? , 2010, Journal of the National Cancer Institute.
[9] A. Shevchenko,et al. Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry , 1996, Nature.
[10] Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis , 2015, Familial Cancer.
[11] Loïc Dayon,et al. Analysis of 1508 Plasma Samples by Capillary-Flow Data-Independent Acquisition Profiles Proteomics of Weight Loss and Maintenance , 2019, Molecular & Cellular Proteomics.
[12] R. Holland. What makes a good biomarker? , 2016, Advances in Precision Medicine.
[13] Richard E Higgs,et al. Label-free LC-MS method for the identification of biomarkers. , 2008, Methods in molecular biology.
[14] S. Badve,et al. Predictive Biomarkers in Oncology , 2019, Springer International Publishing.
[15] D. Liebler,et al. Targeted Quantitation of Proteins by Mass Spectrometry , 2013, Biochemistry.
[16] M. Mann,et al. Mass spectrometry–based proteomics turns quantitative , 2005, Nature chemical biology.
[17] Christoph H Borchers,et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.
[18] Douglas B. Johnson,et al. Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma* , 2017, Molecular & Cellular Proteomics.
[19] R. Zahedi,et al. Quantifying Missing (Phospho)Proteome Regions with the Broad-Specificity Protease Subtilisin. , 2017, Analytical chemistry.
[20] Christoph H Borchers,et al. Method and platform standardization in MRM-based quantitative plasma proteomics. , 2013, Journal of proteomics.
[21] H. Cooper,et al. Compound heterozygotes and beta‐thalassemia: Top‐down mass spectrometry for detection of hemoglobinopathies , 2014, Proteomics.
[22] Judy H. Cho,et al. Finding the missing heritability of complex diseases , 2009, Nature.
[23] Min-Yuan Chou,et al. Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry. , 2015, Analytical chemistry.
[24] M. Moran,et al. Evosep One Enables Robust Deep Proteome Coverage Using Tandem Mass Tags while Significantly Reducing Instrument Time. , 2019, Journal of proteome research.
[25] Melvin A. Park,et al. Trends in trapped ion mobility – Mass spectrometry instrumentation , 2019, TrAC Trends in Analytical Chemistry.
[26] K. Mechtler,et al. Improved Sensitivity in Low-Input Proteomics Using Micropillar Array-Based Chromatography , 2019, bioRxiv.
[27] B. Kuster,et al. A bead-based western for high-throughput cellular signal transduction analyses , 2016, Nature Communications.
[28] Viswanath Devanarayan,et al. Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.
[29] Thomas Stoll,et al. Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II , 2017, Diabetes Care.
[30] M. Lowenthal,et al. Quantification of cardiac troponin I in human plasma by immunoaffinity enrichment and targeted mass spectrometry , 2018, Analytical and Bioanalytical Chemistry.
[31] Daniel T Holmes,et al. Quantitation of Insulin Analogues in Serum Using Immunoaffinity Extraction, Liquid Chromatography, and Tandem Mass Spectrometry. , 2016, Methods in molecular biology.
[32] K. Strimbu,et al. What are biomarkers? , 2010, Current opinion in HIV and AIDS.
[33] Yafeng Zhu,et al. In-depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta , 2019, eLife.
[34] M. Vogeser,et al. An endoglycosidase-assisted LC-MS/MS-based strategy for the analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using prostate-specific antigen (PSA) as example. , 2018, Clinica chimica acta; international journal of clinical chemistry.
[35] Haixu Tang,et al. Interlaboratory Study on Differential Analysis of Protein Glycosylation by Mass Spectrometry: The ABRF Glycoprotein Research Multi-Institutional Study 2012* , 2013, Molecular & Cellular Proteomics.
[36] D. Hilbert,et al. The discovery and development of belimumab: the anti-BLyS–lupus connection , 2012, Nature Biotechnology.
[37] R. Zahedi. Joining forces: studying multiple post-translational modifications to understand dynamic disease mechanisms , 2016, Expert review of proteomics.
[38] J. Ioannidis,et al. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. , 2011, JAMA.
[39] Carl-Magnus Clausson,et al. Insufficient antibody validation challenges oestrogen receptor beta research , 2017, Nature Communications.
[40] R. Popp,et al. How iMALDI can improve clinical diagnostics. , 2018, The Analyst.
[41] Jeffrey W. Clark,et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.
[42] Vicky A Legrys,et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. , 2008, The Journal of pediatrics.
[43] R. Branca,et al. Isoelectric point-based fractionation by HiRIEF coupled to LC-MS allows for in-depth quantitative analysis of the phosphoproteome , 2017, Scientific Reports.
[44] J. Yates,et al. Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. , 1995, Analytical chemistry.
[45] René P Zahedi,et al. The next level of complexity: Crosstalk of posttranslational modifications , 2014, Proteomics.
[46] Ryan W. Benz,et al. A large-scale and robust dynamic MRM study of colorectal cancer biomarkers. , 2018, Journal of proteomics.
[47] Bruno Manadas,et al. SWATH‐MS as a tool for biomarker discovery: From basic research to clinical applications , 2017, Proteomics.
[48] K. Dhingra. Oncology 2020: a drug development and approval paradigm. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] J. R. Perkins,et al. Nanoscale separations: Capillary liquid chromatography-mass spectrometry and capillary zone electrophoresis-mass spectrometry for the determination of peptides and proteins , 1991 .
[50] L. Sanders. From Thebes to Toronto and the 21st Century: An Incredible Journey , 2002 .
[51] Steven A Carr,et al. Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.
[52] M. Daly,et al. Genome-wide association studies for common diseases and complex traits , 2005, Nature Reviews Genetics.
[53] Pei Wang,et al. The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline , 2008, Proteomics. Clinical applications.
[54] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[55] Mathias Wilhelm,et al. Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning , 2019, Nature Methods.
[56] Darryl B. Hardie,et al. Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. , 2014, Biochimica et biophysica acta.
[57] Wilhelm Schänzer,et al. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions , 2014, Expert review of proteomics.
[58] Patrick M M Bossuyt,et al. Quantifying the accuracy of a diagnostic test or marker. , 2012, Clinical chemistry.
[59] Holly Janes,et al. Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.
[60] M. Huss,et al. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics , 2013, Nature Methods.
[61] Marius Ilie,et al. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients , 2016, Virchows Archiv.
[62] L. Deterding,et al. Nanoscale separations combined with tandem mass spectrometry. , 1991, Journal of chromatography.
[63] Yanbao Yu,et al. S-Trap, an Ultrafast Sample-Preparation Approach for Shotgun Proteomics. , 2018, Journal of proteome research.
[64] David Moher,et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. , 2003, Clinical chemistry.
[65] Yiling Lu,et al. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. , 2017, Cancer cell.
[66] Yuan-Tsong Chen,et al. A marker for Stevens–Johnson syndrome , 2004 .
[67] H. Towbin,et al. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[68] A. Jaffe,et al. Troponin: the biomarker of choice for the detection of cardiac injury , 2005, Canadian Medical Association Journal.
[69] D. Chan,et al. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges , 2013, Clinical Proteomics.
[70] Ronald J Moore,et al. Enhancing bottom‐up and top‐down proteomic measurements with ion mobility separations , 2015, Proteomics.
[71] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[72] D. Pal,et al. Mass Spectrometry-Based Diagnosis of Hemoglobinopathies: A Potential Tool for the Screening of Genetic Disorder , 2016, Biochemical Genetics.
[73] Tanveer S. Batth,et al. Protein Aggregation Capture on Microparticles Enables Multipurpose Proteomics Sample Preparation* , 2019, Molecular & Cellular Proteomics.
[74] Darryl B. Hardie,et al. A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. , 2010, Journal of proteome research.
[75] U. Scherf,et al. Approval of novel biomarkers: FDA's perspective and major requests , 2010, Scandinavian journal of clinical and laboratory investigation. Supplementum.
[76] C. Eyers,et al. RePLiCal: A QconCAT Protein for Retention Time Standardization in Proteomics Studies. , 2016, Journal of proteome research.
[77] P. Sundgren,et al. Ultrasensitive Immunoprofiling of Plasma Extracellular Vesicles Identifies Syndecan-1 as a Potential Tool for Minimally Invasive Diagnosis of Glioma , 2019, Clinical Cancer Research.
[78] Matthias Mann,et al. Parallel Accumulation-Serial Fragmentation (PASEF): Multiplying Sequencing Speed and Sensitivity by Synchronized Scans in a Trapped Ion Mobility Device. , 2015, Journal of proteome research.
[79] J. Cadeddu,et al. Spurious prostate‐specific antigen (PSA) recurrence after radical prostatectomy: Interference by human antimouse heterophile antibodies , 2007, International journal of urology : official journal of the Japanese Urological Association.
[80] Eugene A. Kapp,et al. Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly‐available database , 2005, Proteomics.
[81] Melvin A. Park,et al. Online Parallel Accumulation–Serial Fragmentation (PASEF) with a Novel Trapped Ion Mobility Mass Spectrometer* , 2018, Molecular & Cellular Proteomics.
[82] W. Catalona,et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. , 2010, The Journal of urology.
[83] Matthias Mann,et al. Revisiting biomarker discovery by plasma proteomics , 2017, Molecular systems biology.
[84] Knut Reinert,et al. OpenMS – An open-source software framework for mass spectrometry , 2008, BMC Bioinformatics.
[85] J. Olsen,et al. Off-line high-pH reversed-phase fractionation for in-depth phosphoproteomics. , 2014, Journal of proteome research.
[86] Steven P Gygi,et al. Streamlined Tandem Mass Tag (SL-TMT) Protocol: An Efficient Strategy for Quantitative (Phospho)proteome Profiling Using Tandem Mass Tag-Synchronous Precursor Selection-MS3. , 2018, Journal of proteome research.
[87] C. Borchers,et al. An online 2D-reversed-phase - Reversed-phase chromatographic method for sensitive and robust plasma protein quantitation. , 2017, Journal of proteomics.
[88] C. E. Parker,et al. Mass-spectrometry-based clinical proteomics--a review and prospective. , 2010, The Analyst.
[89] R. Zahedi,et al. Proteome-wide detection of S-nitrosylation targets and motifs using bioorthogonal cleavable-linker-based enrichment and switch technique , 2019, Nature Communications.
[90] A. Vlahou,et al. Development and Validation of Multiple Reaction Monitoring (MRM) Assays for Clinical Applications. , 2019, Methods in molecular biology.
[91] Sudhir Srivastava,et al. A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[92] Terry M Therneau,et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.
[93] C. Borchers,et al. Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors. , 2017, Analytical chemistry.
[94] Blagoy Blagoev,et al. UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites , 2018, Nature Structural & Molecular Biology.
[95] Changxiao Liu,et al. Direct comparison of LC-MS/MS and RIA methods for the pharmacokinetics assessment of human insulin in preclinical development. , 2018, Biomedical chromatography : BMC.
[96] Oliver M. Bernhardt,et al. Extending the Limits of Quantitative Proteome Profiling with Data-Independent Acquisition and Application to Acetaminophen-Treated Three-Dimensional Liver Microtissues* , 2015, Molecular & Cellular Proteomics.
[97] Jeffrey W. Smith,et al. Mass Spectrometry-Based Label-Free Quantitative Proteomics , 2009, Journal of biomedicine & biotechnology.
[98] D. Matei,et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.
[99] Youngsoo Kim,et al. Method Validation by CPTAC Guidelines for Multi-protein Marker Assays Using Multiple Reaction Monitoring-mass Spectrometry , 2019, Biotechnology and Bioprocess Engineering.
[100] Christoph H Borchers,et al. Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry , 2018, Expert review of proteomics.
[101] D. N. Perkins,et al. Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.
[102] Ben Birkman,et al. The Cystic Fibrosis Foundation , 2017 .
[103] G. Jarvik,et al. Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics. , 2015, Journal of proteomics.
[104] Yassene Mohammed,et al. PeptidePicker: a scientific workflow with web interface for selecting appropriate peptides for targeted proteomics experiments. , 2014, Journal of proteomics.
[105] R. Bast,et al. Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. , 2013, Clinical chemistry.
[106] D. Chan,et al. The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-Cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[107] J. Moul,et al. Prostate specific antigen recurrence after definitive therapy. , 2007, The Journal of urology.
[108] H. Woo,et al. Current Status of Biomarkers for Prostate Cancer , 2013, International journal of molecular sciences.
[109] Erin E. Chambers,et al. Multidimensional LC-MS/MS enables simultaneous quantification of intact human insulin and five recombinant analogs in human plasma. , 2014, Analytical chemistry.
[110] Albert Sickmann,et al. Systematic and quantitative comparison of digest efficiency and specificity reveals the impact of trypsin quality on MS-based proteomics. , 2012, Journal of proteomics.
[111] Loïc Dayon,et al. Obesity shows preserved plasma proteome in large independent clinical cohorts , 2018, Scientific Reports.
[112] Juncong Yang,et al. MRM‐based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma , 2012, Proteomics.
[113] Thomas Stoll,et al. Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease , 2017, EuPA open proteomics.
[114] Gary D Bader,et al. The human genome and drug discovery after a decade. Roads (still) not taken , 2011, 1102.0448.
[115] Scott R. Kronewitter,et al. Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. , 2012, Journal of proteomics.
[116] Ruedi Aebersold,et al. Targeted proteomic strategy for clinical biomarker discovery , 2009, Molecular oncology.
[117] Mehdi Mirzaei,et al. Inter-laboratory evaluation of instrument platforms and experimental workflows for quantitative accuracy and reproducibility assessment , 2015 .
[118] Bernard F King,et al. Volume progression in polycystic kidney disease. , 2006, The New England journal of medicine.
[119] L. McDonnell,et al. Set of Novel Automated Quantitative Microproteomics Protocols for Small Sample Amounts and Its Application to Kidney Tissue Substructures. , 2016, Journal of proteome research.
[120] E. Lundberg,et al. Antibody performance in western blot applications is context-dependent. , 2014, Biotechnology Journal.
[121] Derek J. Bailey,et al. Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics* , 2012, Molecular & Cellular Proteomics.
[122] Y. Kooyk,et al. The tumour glyco-code as a novel immune checkpoint for immunotherapy , 2018, Nature Reviews Immunology.
[123] C. Borchers,et al. An MRM‐Based Cytokeratin Marker Assay as a Tool for Cancer Studies: Application to Lung Cancer Pleural Effusions , 2018, Proteomics. Clinical applications.
[124] M. Panteghini,et al. Standardisation of cardiac troponin I measurement: past and present , 2010, Pathology.
[125] Matthias Mann,et al. A Novel LC System Embeds Analytes in Pre-formed Gradients for Rapid, Ultra-robust Proteomics* , 2018, Molecular & Cellular Proteomics.
[126] J. Senior. Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges , 2014, Drug Safety.
[127] B. Domon,et al. Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer* , 2012, Molecular & Cellular Proteomics.
[128] N. Anderson,et al. Mass spectrometry measurements of prostate-specific antigen (PSA) peptides derived from immune-extracted PSA provide a potential strategy for harmonizing immunoassay differences. , 2014, American journal of clinical pathology.
[129] C. Borchers,et al. Improving the biomarker pipeline. , 2010, Clinical chemistry.
[130] J. Fine,et al. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[131] C. Libioulle,et al. 3-years experience review of neonatal screening for hemoglobin disorders using tandem mass spectrometry. , 2011, Clinica chimica acta; international journal of clinical chemistry.
[132] P. Lescuyer,et al. Identification of hemoglobin variants by top-down mass spectrometry using selected diagnostic product ions , 2015, Analytical and Bioanalytical Chemistry.
[133] Jan L.A. Voskuil,et al. The challenges with the validation of research antibodies , 2017, F1000Research.
[134] Richard D. Smith. Mass spectrometry in biomarker applications: from untargeted discovery to targeted verification, and implications for platform convergence and clinical application. , 2012, Clinical chemistry.
[135] Yassene Mohammed,et al. A standardized kit for automated quantitative assessment of candidate protein biomarkers in human plasma. , 2015, Bioanalysis.
[136] Wilhelm Schänzer,et al. Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls. , 2012, Methods.
[137] Thomas Laurell,et al. Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms. , 2010, Journal of proteomics.